Two DNA-PK selective inhibitors, KU-0060648 and NU7441, were employed as probe to investigate the regulatory role of DNA-PK during DDR in the CtBP1/2 KD ovarian cancer cells. Here, PRKDC is linked to ovarian carcinoma.